Predicting Human Toxicities: A BioMAP® Platform Narrated Case Study
The ability to predict adverse human health effects for toxicity testing or drug discovery, to screen large numbers of molecules for their impact on human disease biology, and to reduce, refine, and replace the use of animals in agreement with regulatory guidelines make the BioMAP® Platform an ideal new approach methodology for next-generation risk assessment. This narrated case study highlights the use of BioMAP Toxicity Signature Analysis for identifying human toxicities of PFAS molecules.